Key Metrics
CiteScore 

2.9
H-Index 

17
SJR 

Q2Pharmacology

SNIP 

0.78
Recommended pre-submission checks
Powered by 

Topics Covered on PharmacoEconomics - Open
PharmacoEconomics - Open Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | SPRINGER INT PUBL AG |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | EUR 2790 | USD 3490 | GBP 2390 |
| Publication Time | 8 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 2017 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Publication Time | 8 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in PharmacoEconomics - Open ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in PharmacoEconomics - Open
Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.
- 29 Jan 2026
- PharmacoEconomics - open
Assessing the Expected Costs of Continuous Remote Monitoring for Post-Discharge Home Use and the Readmission Reduction Required to Achieve Cost Neutrality.
- 27 Jan 2026
- PharmacoEconomics - open
A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care.
- 23 Jan 2026
- PharmacoEconomics - open
Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa.
- 23 Jan 2026
- PharmacoEconomics - open
Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis.
- 20 Jan 2026
- PharmacoEconomics - open
Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective.
- 14 Jan 2026
- PharmacoEconomics - open
Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.
- 29 Jan 2026
- PharmacoEconomics - open
Assessing the Expected Costs of Continuous Remote Monitoring for Post-Discharge Home Use and the Readmission Reduction Required to Achieve Cost Neutrality.
- 27 Jan 2026
- PharmacoEconomics - open
A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care.
- 23 Jan 2026
- PharmacoEconomics - open
Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa.
- 23 Jan 2026
- PharmacoEconomics - open
Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis.
- 20 Jan 2026
- PharmacoEconomics - open
Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective.
- 14 Jan 2026
- PharmacoEconomics - open